JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB262333

Human PDE3B knockout MCF7 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PDE3B KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 5 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human PDE3B knockout MCF7 cell line (AB262333)
  • Sanger seq

Unknown

Sanger Sequencing - Human PDE3B knockout MCF7 cell line (AB262333)

Allele-1 : 5 bp deletion in exon1

Sanger Sequencing - Human PDE3B knockout MCF7 cell line (AB262333)
  • Sanger seq

Unknown

Sanger Sequencing - Human PDE3B knockout MCF7 cell line (AB262333)

Allele-2 : 1 bp insertion in exon 1.

Key facts

Cell type

MCF7

Species or organism

Human

Tissue

Breast

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 5 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab262333-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab257303 Human wild-type MCF7 cell line", "number":"AB262333-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab262333 Human PDE3B knockout MCF7 cell line", "number":"AB262333-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab262333-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab257303 Human wild-type MCF7 cell line", "number":"AB262333-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab262333 Human PDE3B knockout MCF7 cell line", "number":"AB262333-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab262333-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab262333 Human PDE3B knockout MCF7 cell line", "number":"AB262333-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab262333-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab262333 Human PDE3B knockout MCF7 cell line", "number":"AB262333-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PDE3B
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • Slow to trypsinise.
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 5-7x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

MEM + 10% FBS + 0.01 mg/ml bovine insulin

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PDE3B also known as cGMP-inhibited phosphodiesterase B is an enzyme with a role in cyclic nucleotide signaling. It possesses a molecular mass of approximately 133 kDa. PDE3B predominantly gets expressed in adipose tissue liver and to some extent in the heart. It breaks down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which play key roles in cellular signaling. By hydrolyzing these cyclic nucleotides into their non-cyclic forms PDE3B regulates intracellular levels of these molecules.
Biological function summary

In adipose tissue and liver PDE3B modulates lipogenesis and lipolysis which are vital processes for energy balance. This enzyme interacts with signaling pathways that involve protein kinase A (PKA) and insulin signaling. PDE3B operates as part of larger protein complexes and influences the metabolic rate by regulating the availability of the cAMP for phosphorylation reactions. The activity of PDE3B links closely to the control of energy homeostasis due to its regulatory function on lipid metabolism.

Pathways

PDE3B is integral to the insulin signaling pathway and adiponectin signaling pathway both important in glucose and lipid homeostasis. Within these pathways it functions alongside proteins like AKT and PKA where its activity modulates their signaling efficiency. By controlling the balance of cAMP PDE3B influences signaling cascades that are important for the adaptive cellular responses to hormones and nutrients.

PDE3B connects to conditions such as obesity and type 2 diabetes due to its involvement in energy homeostasis and lipid metabolism. In type 2 diabetes the dysregulation of PDE3B activity affects insulin signaling and glucose uptake. Additionally in the context of obesity PDE3B activity shifts the balance of lipolysis and lipogenesis influencing adipose tissue mass and function. Proteins such as insulin receptors and PKA become closely tied to PDE3B in these disorders highlighting its role in metabolic disease mechanisms.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com